Cellosaurus logo
expasy logo

Cellosaurus 22Rv1 (CVCL_1045)

[Text version]
Cell line name 22Rv1
Synonyms 22RV1; 22Rv-1; 22rV1; CWR-22rv1; CWR22-Rv1; CWR22R-V1; CWR22-R1; CWR22Rv1; CWR22R
Accession CVCL_1045
Resource Identification Initiative To cite this cell line use: 22Rv1 (RRID:CVCL_1045)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: TCGA-110-CL cell line panel.
Virology: Contains at least 10 integrated copies of xenotropic murine leukemia virus-related virus (XMRV) genome and produces a high titer of the virus (PubMed=19403664; PubMed=30629668).
Doubling time: ~49 hours (PubMed=10462204); 55 hours (PubMed=25984343); 63 hours (from cell counting), 94 hours (from absorbance) (DOI=10.5897/IJBMBR2013.0154); 40 hours (ATCC=CRL-2505); 40-60 hours (DSMZ=ACC-438); ~41 hours (PBCF); 24.07 hours (GrayJW panel).
Microsatellite instability: Instable (MSI-high) (PubMed=23671654; PubMed=31068700; Sanger).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from sampling site: Prostate.
Sequence variations
  • Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
  • Mutation; HGNC; 7133; KMT2D; Simple; p.Gln3158Ter (c.9472C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
  • Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Arg (c.1637A>G); ClinVar=VCV000045466; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
  • Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Heterozygous (PubMed=14518029; ATCC; Cosmic-CLP; DepMap).
Genome ancestry Source: PubMed=30894373

Origin% genome
Native American0.23
East Asian, North0.52
East Asian, South0
South Asian0.27
European, North67.46
European, South30.62
Disease Prostate carcinoma (NCIt: C4863)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_3967 (CWR22)
CVCL_4Y35 (22Rv1 R)CVCL_A6PG (22Rv1-CabR1)CVCL_A6PH (22Rv1-CabR2)
CVCL_WZ28 (22Rv1-SL)CVCL_ZC64 (22Rv1-undup1)CVCL_ZC65 (22Rv1-undup2)
CVCL_ZC66 (22Rv1-undup3)CVCL_RS39 (22RV1rYM155_300nM)CVCL_KS53 (CellSensor Gli-bla 22Rv1)
Sex of cell Male
Age at sampling Adult
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; DSMZ; ECACC; PubMed=14518029; PubMed=25877200; PubMed=27271795; PubMed=31006810

D3S135814,15 (PubMed=14518029)
15 (DSMZ; PubMed=25877200; PubMed=27271795)
D5S81811,12 (Cosmic-CLP; ECACC; PubMed=31006810)
11,12,13 (ATCC; DSMZ; PubMed=14518029)
11,13 (PubMed=25877200; PubMed=27271795)
D7S8209,10,11 (ATCC; DSMZ; PubMed=25877200; PubMed=27271795)
10,11 (Cosmic-CLP; ECACC; PubMed=14518029; PubMed=31006810)
D8S117912,13,14 (DSMZ; PubMed=14518029; PubMed=27271795)
13,14 (PubMed=25877200)
D13S3178,9,12 (PubMed=14518029)
9,12 (DSMZ; PubMed=25877200; PubMed=27271795; PubMed=31006810)
Penta D9,12
Penta E5,13
vWA14,15,20,21 (DSMZ)
15,20,21 (PubMed=14518029)
15,21 (ATCC; Cosmic-CLP; ECACC; PubMed=25877200; PubMed=27271795; PubMed=31006810)

Run an STR similarity search on this cell line
Web pages https://www.synapse.org/#!Synapse:syn31544528

PubMed=10462204; DOI=10.1007/s11626-999-0115-4
Sramkoski R.M., Pretlow T.G. II, Giaconia J.M., Pretlow T.P., Schwartz S., Sy M.-S., Marengo S.R., Rhim J.S., Zhang D., Jacobberger J.W.
A new human prostate carcinoma cell line, 22Rv1.
In Vitro Cell. Dev. Biol. Anim. 35:403-409(1999)

PubMed=12725112; DOI=10.1385/1-59259-372-0:21
Russell P.J., Kingsley E.A.
Human prostate cancer cell lines.
Methods Mol. Med. 81:21-39(2003)

PubMed=14518029; DOI=10.1002/pros.10290
van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.
Molecular characterization of human prostate carcinoma cell lines.
Prostate 57:205-225(2003)

PubMed=14518030; DOI=10.1002/pros.10291
van Bokhoven A., Caires A., Maria M.D., Schulte A.P., Lucia M.S., Nordeen S.K., Miller G.J., Varella-Garcia M.
Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines.
Prostate 57:226-244(2003)

van Bokhoven A.
Models for prostate cancer. Molecular characterization and critical appraisal of human prostate carcinoma cell lines.
Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands

PubMed=15486987; DOI=10.1002/pros.20158
Zhao H., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R., Brooks J.D.
Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.
Prostate 63:187-197(2005)

PubMed=19403664; DOI=10.1128/JVI.00546-09
Knouf E.C., Metzger M.J., Mitchell P.S., Arroyo J.D., Chevillet J.R., Tewari M., Miller A.D.
Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells.
J. Virol. 83:7353-7356(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21248069; DOI=10.1158/0008-5472.CAN-10-1998
Li Y., Alsagabi M., Fan D., Bova G.S., Tewfik A.H., Dehm S.M.
Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.
Cancer Res. 71:2108-2117(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

Iloki Assanga S.B., Gil-Salido A.A., Lewis Lujan L.M., Rosas-Durazo A., Acosta-Silva A.L., Rivera-Castaneda E.G., Rubio-Pino J.L.
Cell growth curves for different cell lines and their relationship with biological activities.
Int. J. Biotechnol. Mol. Biol. Res. 4:60-70(2013)

PubMed=23117885; DOI=10.1158/0008-5472.CAN-12-3630
Li Y., Chan S.-C., Brand L.J., Hwang T.H., Silverstein K.A.T., Dehm S.M.
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Cancer Res. 73:483-489(2013)

PubMed=23671654; DOI=10.1371/journal.pone.0063056
Lu Y.-H., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=27271795; DOI=10.1002/pros.23190
Shourideh M., DePriest A., Mohler J.L., Wilson E.M., Koochekpour S.
Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line.
Prostate 76:1067-1077(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28145883; DOI=10.18632/oncotarget.14850
Nouri M., Caradec J., Lubik A.A., Li N., Hollier B.G., Takhar M., Altimirano-Dimas M., Chen M.-Q., Roshan-Moniri M., Butler M., Lehman M., Bishop J., Truong S., Huang S.-C., Cochrane D., Cox M., Collins C., Gleave M., Erho N., Alshalafa M., Davicioni E., Nelson C., Gregory-Evans S., Karnes R.J., Jenkins R.B., Klein E.A., Buttyan R.
Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.
Oncotarget 8:18949-18967(2017)

PubMed=28928128; DOI=10.1158/0008-5472.CAN-17-0320
Van Etten J.L., Nyquist M., Li Y., Yang R., Ho Y., Johnson R., Ondigi O., Voytas D.F., Henzler C., Dehm S.M.
Targeting a single alternative polyadenylation site coordinately blocks expression of androgen receptor mRNA splice variants in prostate cancer.
Cancer Res. 77:5228-5235(2017)

PubMed=30629668; DOI=10.1371/journal.pone.0210404
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
Screening human cell lines for viral infections applying RNA-Seq data analysis.
PLoS ONE 14:E0210404-E0210404(2019)

PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132
Hooker S.E. Jr., Woods-Burnham L., Bathina M., Lloyd S.M., Gorjala P., Mitra R., Nonn L., Kimbro K.S., Kittles R.
Genetic ancestry analysis reveals misclassification of commonly used cancer cell lines.
Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31006810; DOI=10.1093/nar/gkz286
Kounatidou E., Nakjang S., McCracken S.R.C., Dehm S.M., Robson C.N., Jones D., Gaughan L.
A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities.
Nucleic Acids Res. 47:5634-5647(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2
Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
Nat. Commun. 10:3574.1-3574.11(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cell line collections ATCC; CRL-2505
BCRC; 60545
CLS; 305037
ECACC; 05092802
KCB; KCB 200731YJ
Cell line databases/resources CLO; CLO_0001199
CLO; CLO_0001200
Cell_Model_Passport; SIDM00499
Cosmic-CLP; 924100
DepMap; ACH-000956
DSMZCellDive; ACC-438
IGRhCellID; 22Rv1
Lonza; 1442
Anatomy/cell type resources BTO; BTO:0002999
Biological sample resources BioSample; SAMN03471600
BioSample; SAMN03472052
BioSample; SAMN05292447
BioSample; SAMN07710012
BioSample; SAMN07710013
BioSample; SAMN07710014
BioSample; SAMN07710015
BioSample; SAMN07710016
BioSample; SAMN07710017
BioSample; SAMN07710018
BioSample; SAMN10988315
Chemistry resources ChEMBL-Cells; CHEMBL3308004
ChEMBL-Targets; CHEMBL612657
GDSC; 924100
PharmacoDB; 22RV1_12_2019
PubChem_Cell_line; CVCL_1045
Encyclopedic resources Wikidata; Q54583380
Experimental variables resources EFO; EFO_0002095
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM91926
GEO; GSM525793
GEO; GSM648815
GEO; GSM827396
GEO; GSM886837
GEO; GSM887900
GEO; GSM1374375
GEO; GSM1633317
GEO; GSM1633318
GEO; GSM1633319
GEO; GSM1669565
GEO; GSM3145703
Polymorphism and mutation databases Cosmic; 924100
Cosmic; 1075276
Cosmic; 1028699
Cosmic; 1071480
Cosmic; 1172629
Cosmic; 1330911
Cosmic; 1689707
Cosmic; 1995323
Cosmic; 2537791
Cosmic; 2580126
Cosmic; 2651766
Cosmic; 2669170
IARC_TP53; 18887
LiGeA; CCLE_229
Progenetix; CVCL_1045
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update21-Mar-2023
Version number43